{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.9","value":"128.38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose, EOI, 2, 4, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, and Cycle 1 Day 8","title":"Part 2 - AUC (0-168 h) for Cys-mcMMAF After First Dose","type":"SECONDARY","unitOfMeasure":"h*ug/mL"}